Beam Therapeutics (BEAM)
Develops base-edited medicines for sickle cell disease and inherited metabolic disorders.
$26.00
After hours+0.08 (+0.31%)
At close$25.92(+2.61%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 106.15% | 109.64M shares | |
|---|---|---|---|
| 286 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.59% | 605.9K shares | |
| 5 holders · as of Jul 29, 2026 | |||
| Adds to | 106.74% | ||
103.29M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 106.74%; nothing is left for Other.
13F, as of Jun 30, 2026
286 holders · 109.64M shares · 60 new positions · 154 increased · 78 reduced · 35 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 12.61M | 12.21% | +156.8K | Aug 13, 2026 |
| Farallon Capital Management LLC | 10.24M | 9.91% | +101.7K | Aug 14, 2026 |
| Ark Investment Management LLC | 10.23M | 9.91% | −1.90M | Aug 14, 2026 |
| BlackRock, Inc. | 9.00M | 8.71% | +510.0K | Aug 7, 2026 |
| State Street Corp | 5.83M | 5.64% | +127.9K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 4.92M | 4.76% | +350.5K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.60M | 4.45% | +222.1K | Aug 13, 2026 |
| Arch Venture Management, LLC | 4.54M | 4.40% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 12.60% | 12.75M | 13G | Feb 5, 2026 |
| ARK Investment Management LLC | 12.29% | 12.47M | 13G | Feb 3, 2026 |
| BlackRock, Inc. | 7.50% | 7.50M | 13G | Apr 17, 2025 |
| State Street Corporation | 5.20% | 5.23M | 13G | Feb 9, 2026 |
| Vanguard Capital Management | 5.02% | 5.12M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 27, 2026 | Amy Simonofficer: Chief Medical Officer | Sale | 16,667 | $25.74 | 85,696 |
| Jun 30, 2026 | Amy Simonofficer: Chief Medical Officer | Sale | 373 | $34.73 | 102,363 |
| Jun 29, 2026 | John M. Evansdirector, officer: CEO | Sale · 2 lots | 25,000 | $35.49 | 1,047,205 |
| Jun 30, 2026 | John M. Evansdirector, officer: CEO | Sale · 2 lots | 25,000 | $34.31 | 1,047,205 |
| Jun 26, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sale | 251,488 | $35.26 | 854,583 |
| Jun 25, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sale | 33,372 | $35.12 | 1,106,071 |
| Apr 1, 2026 | Giuseppe Ciaramellaofficer: President | Sale | 11,810 | $24.58 | 218,406 |
| Apr 1, 2026 | Christine Bellonofficer: Chief Legal Officer | Sale | 5,956 | $24.58 | 109,711 |
| Apr 1, 2026 | Bethany J. Cavanaghofficer: SVP, Finance and Treasurer | Sale | 3,242 | $24.58 | 51,171 |
| Apr 1, 2026 | Amy Simonofficer: Chief Medical Officer | Sale | 6,700 | $24.58 | 102,735 |
House and Senate disclosures
Not reported.